Your browser is no longer supported. Please, upgrade your browser.
Settings
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own3.90% Shs Outstand69.61M Perf Week-77.30%
Market Cap2.01B Forward P/E- EPS next Y-1.07 Insider Trans-2.77% Shs Float52.93M Perf Month-77.67%
Income-63.40M PEG- EPS next Q-0.55 Inst Own81.70% Short Float6.72% Perf Quarter-83.33%
Sales69.20M P/S29.06 EPS this Y13.60% Inst Trans-0.18% Short Ratio1.80 Perf Half Y-79.33%
Book/sh5.19 P/B2.11 EPS next Y70.90% ROA-12.10% Target Price- Perf Year-79.57%
Cash/sh2.05 P/C5.35 EPS next 5Y- ROE-16.10% 52W Range9.55 - 70.29 Perf YTD-82.28%
Dividend- P/FCF- EPS past 5Y4.80% ROI-13.50% 52W High-84.85% Beta1.45
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low11.52% ATR5.24
Employees133 Current Ratio7.10 Sales Q/Q73.30% Oper. Margin-90.00% RSI (14)15.13 Volatility50.10% 15.81%
OptionableYes Debt/Eq0.07 EPS Q/Q-20.60% Profit Margin-91.50% Rel Volume2.86 Prev Close10.97
ShortableYes LT Debt/Eq0.04 EarningsApr 29 AMC Payout- Avg Volume1.98M Price10.65
Recom1.60 SMA20-74.03% SMA50-78.51% SMA200-80.69% Volume4,789,911 Change-2.92%
May-07-21Downgrade SVB Leerink Outperform → Mkt Perform
May-07-21Downgrade Stifel Buy → Hold $93 → $26
May-07-21Downgrade Raymond James Strong Buy → Outperform
May-07-21Downgrade Piper Sandler Overweight → Neutral $80 → $25
May-07-21Downgrade JP Morgan Neutral → Underweight $57 → $17
Mar-02-21Reiterated H.C. Wainwright Buy $83 → $101
Mar-02-21Initiated Stifel Buy $93
Oct-29-20Downgrade JP Morgan Overweight → Neutral $63 → $60
Jun-17-20Initiated BTIG Research Buy $70
May-27-20Initiated Wells Fargo Overweight $79
May-12-20Reiterated H.C. Wainwright Buy $60 → $69
Jan-24-20Reiterated H.C. Wainwright Buy $40 → $60
Nov-26-19Reiterated Piper Jaffray Overweight $17 → $54
Nov-26-19Reiterated H.C. Wainwright Buy $23 → $40
Mar-27-19Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
Feb-11-19Initiated Piper Jaffray Overweight $20
Sep-07-18Initiated B. Riley FBR Neutral $12.50
Aug-14-18Downgrade JP Morgan Overweight → Neutral
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Initiated H.C. Wainwright Buy $20
May-11-21 02:28PM  
02:05PM  
12:35PM  
11:40AM  
10:00AM  
10:00AM  
09:30AM  
09:06AM  
06:00AM  
05:25AM  
May-10-21 11:21PM  
08:37PM  
07:07PM  
05:58PM  
04:36PM  
04:31PM  
04:00PM  
03:00PM  
02:39PM  
02:30PM  
01:30PM  
01:20PM  
12:40PM  
11:45AM  
11:30AM  
11:00AM  
10:30AM  
10:00AM  
09:00AM  
08:00AM  
06:20AM  
May-09-21 03:22AM  
May-08-21 04:45PM  
01:10PM  
11:30AM  
May-07-21 10:44PM  
07:05PM  
06:56PM  
06:48PM  
04:52PM  
04:30PM  
04:29PM  
04:20PM  
04:00PM  
02:30PM  
02:20PM  
01:48PM  
12:22PM  
12:09PM  
11:30AM  
11:11AM  
11:00AM  
10:17AM  
10:15AM  
10:14AM  
10:03AM  
10:00AM  
09:35AM  
06:47AM  
May-06-21 07:20PM  
07:00PM  
07:00PM  
05:18PM  
05:17PM  
04:40PM  
04:00PM  
03:30PM  
03:05PM  
02:40PM  
02:02PM  
01:45PM  
01:20PM  
12:25PM  
11:10AM  
11:00AM  
10:44AM  
10:42AM  
10:34AM  
10:00AM  
May-05-21 10:26PM  
07:29PM  
06:16PM  
04:00PM  
02:49PM  
02:00PM  
01:16PM  
10:28AM  
10:00AM  
09:35AM  
08:00AM  
02:45AM  
May-04-21 06:00PM  
05:16PM  
04:49PM  
04:06PM  
03:45PM  
02:41PM  
01:23PM  
01:19PM  
12:03PM  
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butt TausifEVP, Chief Operating OfficerMay 07Buy11.0610,870120,24110,870May 10 07:48 PM
Jain RitaDirectorMar 27Option Exercise0.005,251018,226Mar 30 08:45 PM
Parker Geoffrey M.DirectorMar 05Sale56.3830,0001,691,46812,690Mar 08 08:28 PM
Parker Geoffrey M.DirectorMar 04Sale60.201,910114,98042,690Mar 08 08:28 PM
Edwards Thomas A.DirectorMar 02Sale70.061,10077,063119,857Mar 03 08:33 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMar 01Option Exercise10.2433,092338,972118,918Mar 03 08:39 PM
Kwan Pui SanPrincipal Acctg OfficerMar 01Option Exercise10.463,34735,0126,579Mar 01 08:54 PM
Kwan Pui SanPrincipal Acctg OfficerMar 01Sale68.523,347229,3353,232Mar 01 08:54 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMar 01Sale68.4333,0922,264,44385,826Mar 03 08:39 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 09Option Exercise11.027007,71486,526Feb 11 08:02 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 09Sale69.6670048,76585,826Feb 11 08:02 PM
Edwards Thomas A.DirectorFeb 09Sale70.0340028,014120,957Feb 11 07:52 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 08Option Exercise11.027,42081,76893,246Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 08Sale67.307,420499,35185,826Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Option Exercise11.028058,87186,631Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Sale67.0780553,99485,826Feb 08 08:31 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 04Option Exercise10.463,34735,0126,579Feb 08 08:25 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 04Option Exercise11.021,40015,42887,226Feb 08 08:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 04Sale67.141,40093,99585,826Feb 08 08:31 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 04Sale65.003,347217,5553,232Feb 08 08:25 PM
Edwards Thomas A.DirectorFeb 02Sale60.9420,0001,218,844121,357Feb 04 07:58 PM
Kwan Pui SanPrincipal Acctg OfficerJan 25Option Exercise9.704,18440,5647,416Jan 27 07:25 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 25Option Exercise11.021,37515,15287,201Jan 27 08:22 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 25Sale67.031,37592,17285,826Jan 27 08:22 PM
Kwan Pui SanPrincipal Acctg OfficerJan 25Sale65.004,184271,9603,232Jan 27 07:25 PM
Schall Thomas J.President and CEOJan 01Option Exercise0.0087,89902,356,456Jan 07 08:40 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0030,3330135,263Jan 07 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0021,100097,347Jan 07 08:26 PM
Edwards Thomas A.DirectorDec 28Sale61.5010,782663,093141,357Dec 29 06:58 PM
Edwards Thomas A.DirectorDec 24Sale61.1814,218869,904152,139Dec 29 06:58 PM
Kwan Pui SanPrincipal Acctg OfficerDec 15Option Exercise10.0742,593428,94345,825Dec 16 07:46 PM
Schall Thomas J.President and CEODec 15Option Exercise14.3117,619252,1282,286,176Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 15Sale65.0642,5932,771,2373,232Dec 16 07:46 PM
Schall Thomas J.President and CEODec 15Sale65.0117,6191,145,4502,268,557Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 14Option Exercise7.058,95763,15812,189Dec 16 07:46 PM
Schall Thomas J.President and CEODec 14Option Exercise14.3111,153159,5992,279,710Dec 16 07:51 PM
Schall Thomas J.President and CEODec 14Sale65.0311,153725,2462,268,557Dec 16 07:51 PM
Kwan Pui SanPrincipal Acctg OfficerDec 14Sale65.028,957582,3983,232Dec 16 07:46 PM
Vifor (International) Ltd10% OwnerAug 03Sale53.9349,2582,656,6559,194,085Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 31Sale52.3940,4022,116,8259,243,343Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 30Sale54.6048,0812,625,3309,283,745Aug 03 07:10 PM
Vifor (International) Ltd10% OwnerJul 29Sale52.5888,0124,627,4799,331,826Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 28Sale53.5140,1602,149,1179,419,838Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 27Sale53.3234,2361,825,4769,459,998Jul 29 07:55 PM
Vifor (International) Ltd10% OwnerJul 24Sale52.5426,0501,368,7379,494,234Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 23Sale54.1534,5551,871,2979,520,284Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 22Sale55.5872,4694,027,8689,554,839Jul 24 07:53 PM
Vifor (International) Ltd10% OwnerJul 21Sale55.5087,5294,857,6329,627,308Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 20Sale56.0354,5983,059,0539,714,837Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 17Sale55.8647,8902,675,1059,769,435Jul 21 06:32 PM
Vifor (International) Ltd10% OwnerJul 16Sale56.9673,5004,186,7419,817,325Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 15Sale59.2286,2985,110,9719,890,825Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 14Sale58.08100,0005,808,3189,977,123Jul 16 08:00 PM
Vifor (International) Ltd10% OwnerJul 13Sale58.15100,0005,815,02710,077,123Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 10Sale59.9245,8442,747,17210,177,123Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 09Sale59.91100,0005,990,52110,222,967Jul 13 07:18 PM
Vifor (International) Ltd10% OwnerJul 08Sale59.95100,0005,994,74510,322,967Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 07Sale59.2179,3874,700,83810,422,967Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 06Sale58.4486,6905,066,12010,502,354Jul 08 08:39 PM
Vifor (International) Ltd10% OwnerJul 02Sale57.4787,7815,044,43410,589,044Jul 07 06:57 PM
Schall Thomas J.President and CEOJun 15Option Exercise14.312,00028,6202,270,557Jun 16 08:20 PM
Schall Thomas J.President and CEOJun 15Sale65.042,000130,0902,268,557Jun 16 08:20 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 12Option Exercise10.8633,541364,255109,788Jun 16 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 12Option Exercise9.3250,000466,100141,317Jun 16 08:08 PM
Schall Thomas J.President and CEOJun 12Option Exercise14.3188,7531,270,0552,357,310Jun 16 08:20 PM
Schall Thomas J.President and CEOJun 12Sale65.0888,7535,775,8772,268,557Jun 16 08:20 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 12Sale64.5850,0003,229,03591,317Jun 16 08:08 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 12Sale65.1033,5412,183,51976,247Jun 16 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 03Option Exercise5.3110,75057,059104,930Jun 05 07:11 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Option Exercise6.6219,612129,83195,859May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Sale60.3419,6121,183,42376,247May 26 09:04 PM
Tyree James LDirectorMay 23Option Exercise0.007,724013,069May 26 08:59 PM
Parker Geoffrey M.DirectorMay 23Option Exercise0.007,7240111,913May 26 08:55 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Option Exercise6.6240,867270,540117,114May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Sale60.0640,8672,454,52576,247May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Option Exercise6.622,80018,53679,047May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Sale59.992,800167,98676,247May 26 09:04 PM
Schall Thomas J.President and CEOMay 12Option Exercise14.3135,865513,2282,304,422May 12 07:50 PM
Schall Thomas J.President and CEOMay 12Sale57.7535,8652,071,1002,268,557May 12 07:50 PM